Revelation Biosciences Inc (REVB)

[subslover]

Revelation Biosciences (NASDAQ: REVB) stock is up 130% premarket this morning on no really obvious news releases. This follows a 27% price rise in REVB stock yesterday. This is, of course, nice for those stockholders who were in the SPAC process, who have lost 93% of their money since the combination back in January. The question is, well, what's driving this stock price rise? There is no obvious news release to explain it, so we'll have to make some surmises.

Revelation is a clinical-stage biopharmaceutical company focussing on immune system therapeutics and diagnostics. So, there's significant effort and business opportunity in covid, influenza, rhinosinusitis and so on. So far so good, although there doesn't seem to have been any grand announcement about anything from the FDA to explain suh a stock price rise.